The Prevention of Benign Prostatic Hyperplasia (BPH)
December 2016
in “
Medical Hypotheses
”
TLDR A vaccine may prevent benign prostatic hyperplasia (BPH).
The document discussed the development and prevention of benign prostatic hyperplasia (BPH), attributing its cause to repeated colonization and destruction of E. coli in the prostate gland, leading to the release of phospholipase D (PLD) and subsequent production of lysophosphatidic acid (LPA). This process stimulates prostatic smooth muscle growth and affects connective tissue through autocrine and paracrine hormones, with androgens playing a permissive role. The study highlighted the importance of zinc in prostatic fluid, the role of testosterone and dihydrotestosterone (DHT) in prostate development, and the potential involvement of genes and prolactin in BPH. The conclusion emphasized the proven stimulation of LPA by PLD and its dose-related effects on prostatic smooth muscle and connective tissue.